Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
- 27 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 66 (6), 1173-1184
- https://doi.org/10.1007/s00280-010-1406-x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?Journal of Controlled Release, 2007
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free FormDrug Safety, 2001
- Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Annals of Oncology, 2000
- A METHOD FOR ESTIMATING AND TESTING AREA UNDER THE CURVE IN SERIAL SACRIFICE, BATCH, AND COMPLETE DATA DESIGNSJournal of Biopharmaceutical Statistics, 1999
- Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomesCancer, 1999
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979